摘要：免疫球蛋白A肾病(IgAN)是原发性肾小球肾炎的最常见类型，约20%～40%在20年内发展为终末期肾病(ESRD)。IgAN的治疗方案尚未统一，目前仍然没有能够靶向涉及疾病发病机制的关键途径的特定疗法，目前的建议是基于指南证据水平较低的基础上提出的。本文对IgAN的发病机制及现有免疫抑制治疗方法进行了综述，以期为临床治疗IgAN提供新的方向和参考。

    关键词：肾小球肾炎；IgA肾病；免疫抑制剂

    中图分类号：R692.6" " " " " " " " " " " " " " " " 文献标识码：A" " " " " " " " " " " " " " " " " DOI：10.3969/j.issn.1006-1959.2023.14.040

    文章编号：1006-1959(2023)14-0183-05

    Research Progress on Immunosuppressive Therapy for IgA Nephropathy in Adults

    ZHENG Zhuo-long1，LIN Gang1，LUO Mian-na2，XU Yong-zhi2

    (1.Institute of Nephrology，Guangdong Medical University，Zhanjiang 524001，Guangdong，China;

    2.Department of Nephrology，the First Affiliated Hospital of Guangdong Medical University，Zhanjiang 524001，Guangdong，China)

    Abstract：Immunoglobulin A nephropathy (IgAN) is the most common type of primary glomerulonephritis， about 20% to 40% of which develop into end-stage renal disease (ESRD) within 20 years. The treatment of IgAN has not yet been unified， and there is still no specific therapy that can target the key pathways involved in the pathogenesis of the disease. The current recommendations are based on the low level of evidence in the guidelines. This article reviews the pathogenesis of IgAN and the existing immunosuppressive treatment methods of IgAN ......